January 21, 2022

Statement from Reata Pharmaceuticals to Alport Syndrome Foundation and the larger community of Alport syndrome patients and families:

We at Reata are deeply appreciative of your contribution toward the development of bardoxolone methyl, especially your efforts in the conduct of our clinical trials.

For those who are unaware, the outcome of the recent Advisory Committee was negative, despite the FDA’s agreement that the CARDINAL study was positive and met its primary endpoint. Although we are disappointed with the outcome, we appreciate the committee’s discussions regarding bardoxolone, an investigational drug with a novel mechanism of action.

Alport syndrome is one of the most rapidly progressive forms of CKD, with significant unmet need, and we will continue to work with the FDA to answer any questions or concerns they may have while preparing for the upcoming PDUFA date of February 25, 2022.

EAGLE, the open label extension of bardoxolone for patients who completed CARDINAL, will continue.

We remain committed to the development of bardoxolone in chronic kidney disease secondary to Alport syndrome, and we will continue to provide updates as they arise.